Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

• Published in: Journal of hepatology Vol. 42; no. 3; pp. 386 - 392
• Main Authors: Nakamura, Minoru, Shimizu-Yoshida, Yuki, Takii, Yasushi, Komori, Atsumasa, Yokoyama, Terufumi, Ueki, Toshihito, Daikoku, Manabu, Yano, Koji, Matsumoto, Takehiro, Migita, Kiyoshi, Yatsuhashi, Hiroshi, Ito, Masahiro, Masaki, Naohiko, Adachi, Hiroshi, Watanabe, Yukio, Nakamura, Yoko, Saoshiro, Takeo, Sodeyama, Takeshi, Koga, Michiaki, Shimoda, Shinji, Ishibashi, Hiromi
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier B.V 01-03-2005; Elsevier
• Subjects: Anti-gp210 antibody; Antibodies - blood; Biological and medical sciences; Biomarkers - blood; Clinical parameter; Disease-Free Survival; End-stage hepatic failure; Enzyme-Linked Immunosorbent Assay; Female; Gastroenterology. Liver. Pancreas. Abdomen; Humans; Interface hepatitis; Liver Cirrhosis, Biliary - blood; Liver Cirrhosis, Biliary - immunology; Liver Cirrhosis, Biliary - mortality; Liver Cirrhosis, Biliary - therapy; Liver Function Tests; Liver transplantation; Liver Transplantation - physiology; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Male; Medical sciences; Membrane Glycoproteins - immunology; Middle Aged; Nuclear Pore Complex Proteins; Nuclear Proteins - immunology; Other diseases. Semiology; Peptide Fragments - immunology; Primary biliary cirrhosis; Probability; Retrospective Studies; Survival Analysis; Treatment Outcome; Ursodeoxycholic acid; Ursodeoxycholic Acid - therapeutic use; Primary biliary cirrhosis; Clinical parameter; Interface hepatitis; Anti-gp210 antibody; End-stage hepatic failure; Ursodeoxycholic acid; Liver transplantation; Antibody; Hepatic disease; C-Peptide; Terminal; Surveillance; Digestive diseases; Monitoring
• ISSN: 0168-8278; 1600-0641
• DOI: 10.1016/j.jhep.2004.11.016

The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved.
We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC.
Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan.
The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.